LabTurbo Biotech Corporation

LabTurbo AIO SP-qPCR system use the exclusive patented "flow membrane tube vacuum method" as core technology, the process can be completed within two and a half hours, which significantly increases the amount of detection. LabTurbo system has an accuracy rate of over 90 percent, and it can detect infections during the incubation period. Currently, we have obtained the EUA in Taiwan and will soon obtain the EUA from the US FDA.

MAKALOT INDUSTRIAL CO., LTD

【Makalot Textile-based Smart Healthcare Solution】

Makalot Smart Healthcare Clothing is a textile-based smart telemedicine solution, including bio-sensing clothes and a portable tracking sensor.
The detected bio-sensing data, like heart rate, calories, breathe rate, steps, physical fatigue and mental stress, will be collected and uploaded to cloud database, and then delivered to monitoring system. Specialists can easily view these data on visualized interface to get sufficient information of how the user behave periodically.
The total service consists of bio-sensing detection, data storage and monitoring system, and we believed that it would become a great support for health promotion.

Mediland Enterprise Corporation

Established in 1984, Mediland is one of the leading medical equipment manufacturers. From the beginning being the agent of worldwide leading medical equipment suppliers transformed to the operating room equipment manufacturer, Mediland now have reached a solid distribution network with over 150 partners worldwide.
With decades of professional medical equipment expertise, Mediland is focusing on the core of operation room (OR) with a wide range product portfolio including surgical light, surgical table, surgical table accessories, operation room integration systems, pendant systems, and innovated disinfection systems – Hyper Light Disinfection Robot.
During the Covid-19 epidemic, they assisted major hospitals in various regions such as Huoshenshan Hospital and Leishen Mountain Hospital in Mainland China, and targeted intensive care units(ICU) and isolation wards, fever wards, emergency isolation areas, operating rooms, hemodialysis rooms, and cancer wards will be more completely disinfected.
Mediland currently develops and manufactures in Taiwan and China. Carrying out with its spirit " Commitment, Service Orientation and Dedication”, Mediland is an important partner for the healthcare industry.

Motex Healthcare Corp.

1.Safe and effective
Just pull the strings to fasten the airtight film to fit the face shape. This helps to reduce leaks, prevent inward leakage of germs, dust, and haze particles from the gap to reinforce the fitness and tightness of mask. This design allows for better comfort and safety, and is a revolutionary breakthrough in face masks.
The airtight film could be adjusted to meet different levels of filtering requirements: Surgical face mask used in Taiwan (>PFE80%), US specification N95, EU FFP2, or specifications of the same level and is also conforming to the CNS15980 standard of Taiwan for face mask.
2.Brand new design
Innovative design in one piece formation. The two sides of the non-woven fabric of the mask extend inward to the positioning points at the top and the bottom of the mask to fit into one piece. This improves the air tightness and protection of the mask.
3.Economical and practical
Simple and ergonometric design in one piece, ideal for fully automated production at low cost and is economical and practical.

MWG Technologies Co.,Ltd

With advanced sensing technologies, IOT and data analytics, MyGuardian Smart Care System provide continuous in-bed patient monitoring of respiration rate, in-bed movement, and sleep statistics.
The system provides caregivers:
1. Remote patient monitoring and only send alerts for critical events to reduce unnecessary contact
2. Centralized and role-based management on multiple beds simultaneously
3. Continuous monitoring of breathing and alerts when abnormal conditions occur
4. API for data integration with NIS/HIS

National Cheng Kung University / Dr. Jung-Hsien Chiang, distinguished professor research team

MedCheX: Automatic AI-based Pneumonia Detection from Chest X-ray Images and It’s Application to Coronavirus Pandemic (COVID-19)

Automatic detection of pneumonia on X-rays continues to be an important issue. Our system will process the images to assist doctors to determine whether the patients are infected. We first created a ResNeXt based deep learning model to automatically detect the presence of pneumonia. For enhancing the ability of feature extraction in the model, we re-designed the model structure by using the squeeze-and-excitation, which can extract more fine-grained features in the process. Meanwhile, we utilized the Feature Pyramid Network to extend the receptive field on the convolutional kernel, which improved the performance on the pneumonia detection with various location on CXR. In the training phase, we applied the data augmentation, included flipping, rotation, adding noises, and image distortion, to make the model more robust and avoid the model overfitting.
As we continue to face the rapid increase in confirmed Coronavirus cases around the world, we created an AI-based pneumonia detection platform for COVID-19. The system is able to automatically detect high-risk patients with pneumonia that will then send alert information to doctors. With that information, the doctors are then able to make follow-up decisions and provide a treatment plan after the diagnosis. In specific, doctors from Department of Medical Imaging provided us thousands of positive and negative chest x-rays for pneumonia as training set. Our system has already been tested with and adopted by doctors at the NCKU Hospital. The system achieved 95.5% sensitivity and 99.0% specificity to detect the pneumonia symptom, based on 1,363 test images.

National Chiao Tung University/Wen Liang Chen Associate Professor team

Our research uses two core technologies, including the semiconductor manufacturing methods and the special biomaterial to make biosensors with high quality of reproducibility, accuracy and stability, which meets the international criteria of massive production and certificate. Based on the core technologies, our team developed three kinds of COVID-19 biosensors used for viral protein, nucleotide and antibody detection. The three markers indicate the different infection stages of patients, which can help hospitals make precise management to each patient, realizing the goal of precision medicine. Moreover, our team used electrochemical method to develop a convenient and fast-to-use detection machine. The detection machine can deliver the report to the medical personnel in real time and everywhere. We hope this system can not only enhance the efficiency of disease management but also reduce the infectious risk and the burden of the medical personnel.

National Chiao Tung University/Wen Liang Chen Associate Professor team

Our research uses two core technologies, including the semiconductor manufacturing methods and the special biomaterial to make biosensors with high quality of reproducibility, accuracy and stability, which meets the international criteria of massive production and certificate. Based on the core technologies, our team developed three kinds of COVID-19 biosensors used for viral protein, nucleotide and antibody detection. The three markers indicate the different infection stages of patients, which can help hospitals make precise management to each patient, realizing the goal of precision medicine. Moreover, our team used electrochemical method to develop a convenient and fast-to-use detection machine. The detection machine can deliver the report to the medical personnel in real time and everywhere. We hope this system can not only enhance the efficiency of disease management but also reduce the infectious risk and the burden of the medical personnel.

National Defense Medical Center

Our laboratory has developed two strains of hybridoma against SARS-CoV-2 surface spike proteins, named 8a-1 and 27b-2, which produce highly specific and stable monoclonal antibodies. Both antibodies can specifically identify the corona-virus S-2 protein sequence, and will not cross-react with N and E proteins. After testing, it has good protein stability. Using the pairing of the two monoclonal antibodies, we established successfully immunological detection kits for a lateral flow rapid test to detect SARS-CoV-2 virus in human specimens. In spiked sample, as low as 8 x 10,000 PFU virus of single drop would be accurately quantified. A rapid screening kit was developed that can quickly test viruses within 15 minutes.

National Health Research Institutes/ Lab of Dr. Min-Shi Lee

Enterovirus 71 (EV-A71) and polioviruses belong to enterovirus genus. Based on phylogenetic analysis of the most variable VP1 gene, EV-A71 could be classified into 3 major genogroups (A, B and C) including 11 genotypes (A, B1~B5, and C1~C5). Since 1997, different EV-A71 genotypes have caused life-threatening epidemics with severe neurologic complications in Asian countries, including Malaysia, Taiwan, Singapore, Brunei, Vietnam, Cambodia and China. Therefore, development of EV-A71 vaccines is a national priority in these countries. Currently, five vaccine candidates have been evaluated in clinical trials in China (3 candidates got approval), Singapore (1 candidate in phase one), Taiwan (1 candidate in phase one). Overall, these 5 vaccine candidates could not grow very well (~107 PFU/ml) in cells qualified for vaccine production. In addition, genotypes of these 5 candidates include B2 (Singapore), B4 (Taiwan), and three C4 (China) strains, which are different from the current predominant genotype B5 in Taiwan and South-Eastern Asia. Moreover, these vaccine candidates are not produced using bioreactor culture systems and their productivity could not be scaled up readily. Therefore, we generated high-growth EV-A71 genotype B5 virus which could grow to high titers in Vero cells using microcarrier-based bioreactor culture systems. In rabbit studies, the purified vaccine antigens could induce cross-reactive neutralizing antibody titers against 3 EV-A71 major genogroups. For intellectual property protection, we have obtained patent approval in Taiwan and have filed internal patent applications through PCT (Patent Cooperation Treaty). In addition, we have used the high-growth vaccine strain to generate high neutralizing rabbit antisera and mouse monoclonal antibody to develop quantification method of vaccine antigen and join an international collaboration study organized by the WHO reference lab (UK NIBSC). Moreover, we further used the high-growth vaccine virus to establish reverse genetics which will be further employed to generate high-growth vaccine viruses for other enterovirus serotypes and develop multi-valent EV vaccines.